PADI2 and colonic neoplasm: Whereas axitinib targeted the ubiquitin ligase SHPRH to increase ubiquitination and proteasome-mediated degradation of β-catenin [15], nitazoxanide targeted PADI2 to increase citrullination and degradation of β-catenin [17] in colon cancer cells.